Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2019 10:10 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline

BEVERLY, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Companies...
February 19, 2019 09:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis

BEVERLY, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent...
February 11, 2019 10:45 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Files Form 10-Q Quarterly Report

BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with...
January 31, 2019 09:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX

BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the Company is establishing a...
January 22, 2019 08:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease

BEVERLY, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce plans to initiate in 2019 a...
January 14, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease

BEVERLY, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company has...
January 08, 2019 08:00 ET | Source: Innovation Pharmaceuticals, Inc.

Published Studies Confirm Cisplatin Remains Preferred Chemotherapy Component in Head and Neck Cancer Treatment; Innovation Pharmaceuticals on Target with Clinical Trials of Brilacidin for Preventing Severe Oral Mucositis

BEVERLY, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of recent...
January 02, 2019 09:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate

BEVERLY, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U.S. Patent &...
December 17, 2018 07:05 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis

BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company and the U.S. Food...
November 13, 2018 07:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right